Information about Glutamate at memantine.com
Memantine.com | Glutamate: Here you get information about forms of diseases, drugs, therapies, care and latest research results.
Memantine (Axura)
Substance developed by the Merz research organization used to treat dementia and Alzheimer's Disease.
memantine (Namenda) - drug class, medical uses, medication side effects ...
Specifies the medication memantine (Namenda), a drug used for the treatment ... Memantine blocks the receptor and thereby decreases the effects of glutamate. ...
Memantine - Wikipedia, the free encyclopedia
Memantine is also being tested for opioid dependence, systemic lupus ... Glutamate receptor ligands. Ionotropic. NMDA. Agonists; NMDA • Tetrazolylglycine ...
glutamate blockers
... NMDA antagonist, memantine prevents the neurotransmitter glutamate from leading ... an antagonist, memantine prevents the excessive binding of glutamate to NMDA ...
Huntington's Disease Information - HOPES - Memantine, L5
Drug Summary: Memantine is an anti-glutamate and energy-buffering drug. ... NMDA antagonist, memantine prevents the neurotransmitter glutamate from leading ...
Buy Memantine (Ebixa) - Optimal Health Products
Buy Memantine (Ebixa) online - 50 x 10 mg tablets Memantine - brand name Ebixa is a novel new drug that is showing a lot ... Memantine regulates glutamate, a ...
MEMANTINE
Memantine ... Memantine regulates glutamate, a chemical involved in ... Memantine may protect cells against excess glutamate by partially blocking ...
NRM: Waiting for memantine
Waiting for memantine. The glutamate activity blocker promises relief to AD sufferers. ... blocks the activity of glutamate, an essential neurotransmitter in ...
Memantine (Namenda) for Treating Alzheimer's
... detailed information on Memantine (Namenda) for treating ... Memantine may protect cells against excess glutamate by partially blocking NMDA receptors. ...
|
Memantine: targeting glutamate excitotoxicity in A...[Am J Alzheimers Dis Other Demen. 2005 Mar-Apr] - PubMed Result
Unitat Memoria-Alzheimer, Institut Clinic Malalties del Sistema Nervios, Hospital Clinic i Universitari, Barcelona, Spain.The management of dementia has changed since the development of new antidementia drugs. The benefits observed in Alzheimer's disease (AD) with selective cholinergic transmission treatments are mainly symptomatic, without clear evidence of neuroprotection. The hypothesis that glutamate-mediated neurotoxicity is involved in the pathogenesis of AD is finding increasingly more acceptance in the scientific community. Glutamate receptors are overactive, and N-methyl-D-aspartate (NMDA) receptor antagonists have therapeutic potential for the treatment of AD and other neurological disorders. Memantine is a noncompetitive NMDA antagonist that is considered a neuroprotective drug.